Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Alto Neuroscience (ANRO) Enterprise Value (2023 - 2026)

Alto Neuroscience has reported Enterprise Value over the past 4 years, most recently at -$263.8 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$263.8 million for Q1 2026, down 64.08% from a year ago — trailing twelve months through Mar 2026 was -$263.8 million (down 64.08% YoY), and the annual figure for FY2025 was -$176.5 million, down 4.93%.
  • Enterprise Value reached -$263.8 million in Q1 2026 per ANRO's latest filing, down from -$176.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$82.5 million in Q4 2023 and bottomed at -$263.8 million in Q1 2026.
  • Median Enterprise Value over the past 4 years was -$172.3 million (2024), compared with a mean of -$171.8 million.
  • The largest annual shift saw Enterprise Value crashed 103.88% in 2024 before it rose 24.15% in 2025.
  • Over 4 years, Enterprise Value stood at -$82.5 million in 2023, then plummeted by 103.88% to -$168.2 million in 2024, then dropped by 4.93% to -$176.5 million in 2025, then plummeted by 49.45% to -$263.8 million in 2026.
  • Business Quant data shows Enterprise Value for ANRO at -$263.8 million in Q1 2026, -$176.5 million in Q4 2025, and -$137.8 million in Q3 2025.